CKPT (Checkpoint Therapeutics) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Checkpoint Therapeutics ROE % Adjusted to Book Value?

Checkpoint Therapeutics's ROE % for the quarter that ended in Sep. 2024 was 0.00%. Checkpoint Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was N/A. Checkpoint Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was N/A.

Checkpoint Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Checkpoint Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkpoint Therapeutics ROE % Adjusted to Book Value Chart

Checkpoint Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-32.71

-16.37

-19.69

Checkpoint Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Checkpoint Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Checkpoint Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Checkpoint Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Checkpoint Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Checkpoint Therapeutics's ROE % Adjusted to Book Value falls into.

Checkpoint Therapeutics ROE % Adjusted to Book Value Calculation

Checkpoint Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Checkpoint Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Checkpoint Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Checkpoint Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (NAS:CKPT) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

CZTA:Germany

Address

95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453

Website

https://www.checkpointtx.com

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Executives

William Garrett Gray	officer: See Remarks	2 GANSEVOORT STREET,, 9TH FLOOR, NEW YORK NY 10014
Oliviero James F Iii	director, officer: CEO, President and Director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Fortress Biotech, Inc.	10 percent owner	1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Michael S Weiss	director	750 LEXINGTON AVE, NEW YORK NY 10022
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Christian Bechon	director	C/O LFB, 3, AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91940
Barry M Salzman	director	464 COMMON STREET, SUITE 301, BELMONT MA 02478
Scott Boilen	director	2 SKYLINE DRIVE, HAWTHORNE NY 10532
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
David J Horin	officer: Interim CFO	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020